Mirror Biologics, Inc.
15
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
46.7%
7 terminated/withdrawn out of 15 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Immunotherapy for Advanced Liver Cancer
Role: lead
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Role: lead
Immunotherapy for Third Line Metastatic Colorectal Cancer
Role: lead
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Role: lead
Universal Anti-Viral Vaccine for Healthy Elderly Adults
Role: lead
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Role: lead
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Role: lead
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Role: lead
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Role: lead
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Role: lead
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients
Role: lead
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
Role: lead
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
Role: lead
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Role: lead
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
Role: lead
All 15 trials loaded